


**ANGEL ACQUISITION APS**  
**ÅKANDEVEJ 21, 2700 BRØNSHØJ**  
**ANNUAL REPORT**  
**1 JANUARY - 31 DECEMBER 2017**

**The Annual Report has been presented and  
adopted at the Company's Annual General  
Meeting on 31 May 2018**

  
**Anders Birkebæk Clausen**

## CONTENTS

	Page
<b>Company Details</b>	
Company Details.....	3
<b>Statement and Report</b>	
Statement by Board of Executives.....	4
Independent Auditor's Report.....	5-6
<b>Management's Review</b>	
Financial Highlights.....	7
Management's Review.....	8
<b>Financial Statements 1 January - 31 December</b>	
Income Statement.....	9
Balance Sheet.....	10-11
Equity.....	12
Notes.....	13-16
Accounting Policies.....	17-19

## COMPANY DETAILS

<b>Company</b>	Angel Acquisition ApS Åkandevej 21 2700 Brønshøj
	CVR no.: 33 37 52 98 Established: 22 December 2010 Registered Office: Brønshøj Financial Year: 1 January - 31 December
<b>Board of Executives</b>	Frank T. McFaden
<b>Auditor</b>	Ernst & Young Godkendt Revisionspartnerselskab Osvald Helmuths Vej 4 2000 Frederiksberg

## STATEMENT BY BOARD OF EXECUTIVES

Today the Board of Executives have discussed and approved the Annual Report of Angel Acquisition ApS for the year 1 January - 31 December 2017.

The Annual Report is presented in accordance with the Danish Financial Statements Act.

In my opinion the financial statements give a true and fair view of the Company's financial position at 31 December 2017 and of the results of the Company's operations for the financial year 1 January - 31 December 2017.

Further, in my opinion, the Management's review gives a fair review of the matters discussed in the Management's review.

I recommend the Annual Report be approved at the Annual General Meeting.

Copenhagen, 31 May 2018

Board of Executives

DocuSigned by:  
*Frank T. McFaden*  
780E6C599A84400  
Frank T. McFaden

## INDEPENDENT AUDITOR'S REPORT

To the Shareholder of Angel Acquisition ApS

### Opinion

We have audited the financial statements of Angel Acquisition ApS for the financial year 1 January - 31 December 2017, which comprise income statement, balance sheet, statement of changes in equity and notes including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2017 and of the results of the Company's operations for the financial year 1 January - 31 December 2017 in accordance with the Danish Financial Statements Act.

### Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's Responsibilities for the audit of the financial statements" section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### Independence

We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) and additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these rules and requirements.

### Management's Responsibility for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

### Auditor's Responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance as to whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

## INDEPENDENT AUDITOR'S REPORT

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and contents of the financial statements, including the note disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

### Statement on the Management's review

Management is responsible for the Management's review.

Our opinion on the financial statements does not cover the Management's review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of the Management's review.

Copenhagen, 31 May 2018

Ernst & Young Godkendt Revisionspartnerselskab  
CVR-nr. 30 70 02 28

  
Henrik Kronborg Iversen  
State Authorised Public Accountant  
MNE no.: mne24687

  
Rasmus Bloch Jespersen  
State Authorised Public Accountant  
MNE no.: mne35503

## FINANCIAL HIGHLIGHTS

	2017 USD '000	2016 USD '000	2015 USD '000	2014 USD '000	2013 USD '000
<b>Income statement</b>					
Operating loss.....	-48	-39	-44	-38	-52
Financial income and expenses, net.....	-37.827	-46.542	-44.652	-42.201	-7.810
Profit/loss for the year.....	407.402	410.138	1.732.724	-42.239	-7.878
Dividend income.....	445.277	456.719	1.777.420	0	0
<b>Balance sheet</b>					
Balance sheet total.....	6.327.566	6.478.604	6.345.515	6.371.240	6.405.340
Equity.....	6.131.189	5.874.601	5.594.317	5.664.987	5.741.325
<b>Ratios</b>					
Solvency ratio.....	96,9	90,7	88,2	88,9	89,6
Return on equity.....	6,8	7,2	30,8	Neg.	0,0

Financial ratios are calculated in accordance with the recommendation of the Danish Finance Society.

The ratios stated in the list of key figures and ratios have been calculated as follows:

Solvency ratio:

$$\frac{\text{Equity, at year end} \times 100}{\text{Total equity and liabilities, at year end}}$$

Return on equity:

$$\frac{\text{Profit/loss after tax} \times 100}{\text{Average equity}}$$

## MANAGEMENT'S REVIEW

### Principal activities

The objectives of the company are to carry on commercial and manufacturing business as well as financing and investment.

Specifically the company holds investments in group enterprises.

### Development in activities and financial position

The Company's income statement for the year ended 31 December 2017 shows a net profit of USD 407.402 thousand, and the balance sheet at 31 December 2017 shows equity of USD 6.131.189 thousand.

In the annual report 2016, management expressed an expected earnings before tax and any dividend income from investments for 2017, at same level as in 2016 (USD loss of 47 thousand). The realised profit for 2017 was in comparison to the prior years expressed expectations, however impacted by reduced interest expense on intercompany payables.

The Board of Executives recommends distribution of the profit as stated under distribution of profit.

### Significant events after the end of the financial year

No events of material importance for the company's financial position have occurred after the end of the financial year.

### Special risks

The company monitors the risk factors that may affect the operations and financial results on a regular basis.

### Currency risks

The Company's net payments in foreign currencies are usually sold immediately after receipt. There is no hedging of currency risk on foreign currency assets and liabilities.

### Interest rate risk

The interest rate on its loans is on market terms and conditions.

### Future expectations

For 2018, the Company expects to realise profit before tax and any dividend income from investments, at the same level as for 2017 (+/- 10%), depending on the interest level.

### Corporate social responsibility

As the company is a holding company without significant operating activities, policies involving environmental, climate and human rights etc. are not prepared.

### Target figures and policies for the underrepresented gender

As the company's management comprise of one executive and no Board of Directors or other employees, no target figures and policies for the gender composition cf., the Act on Gender Equality, has been set.



INCOME STATEMENT 1 JANUARY - 31 DECEMBER

	Note	2017 USD '000	2016 USD '000
Other external expenses.....	1	-48	-39
<b>GROSS LOSS.....</b>		<b>-48</b>	<b>-39</b>
<b>OPERATING LOSS.....</b>		<b>-48</b>	<b>-39</b>
Dividend income from investments in group enterprises.....		445.277	456.719
Other financial income.....	2	26	270
Other financial expenses.....	3	-37.853	-46.812
<b>PROFIT BEFORE TAX.....</b>		<b>407.402</b>	<b>410.138</b>
Tax on profit for the year.....		0	0
<b>PROFIT FOR THE YEAR.....</b>	4	<b>407.402</b>	<b>410.138</b>

**BALANCE SHEET AT 31 DECEMBER**

<b>ASSETS</b>	<b>Note</b>	<b>2017 USD '000</b>	<b>2016 USD '000</b>
Investments in group enterprises.....		6.324.604	6.324.604
<b>Fixed asset investments.....</b>	<b>5</b>	<b>6.324.604</b>	<b>6.324.604</b>
<b>FIXED ASSETS.....</b>		<b>6.324.604</b>	<b>6.324.604</b>
Receivables from group enterprises.....		0	150.815
Receivables.....		0	150.815
Cash and cash equivalents.....		2.962	3.185
<b>CURRENT ASSETS.....</b>		<b>2.962</b>	<b>154.000</b>
<b>ASSETS.....</b>		<b>6.327.566</b>	<b>6.478.604</b>

**BALANCE SHEET AT 31 DECEMBER**

<b>EQUITY AND LIABILITIES</b>	<b>Note</b>	<b>2017 USD '000</b>	<b>2016 USD '000</b>
Share capital.....		2.921	2.921
Retained profit.....		6.128.268	5.720.865
Proposed dividend.....		0	150.815
<b>EQUITY.....</b>		<b>6.131.189</b>	<b>5.874.601</b>
Payables to group enterprises.....		196.359	603.809
Long-term liabilities.....	6	196.359	603.809
Bank debt.....		0	179
Trade payables.....		18	15
Current liabilities.....		18	194
<b>LIABILITIES.....</b>		<b>196.377</b>	<b>604.003</b>
<b>EQUITY AND LIABILITIES.....</b>		<b>6.327.566</b>	<b>6.478.604</b>
Contingencies etc.	7		
Related parties	8		
Significant events after the end of the financial year	9		
Consolidated financial statements	10		

**EQUITY**

	Share capital	Retained profit	Proposed dividend	Total
Equity at 1 January 2017.....	2.921	5.720.866	150.815	5.874.602
Dividend paid.....			-150.815	-150.815
Proposed distribution of profit.....		407.402		407.402
<b>Equity at 31 December 2017.....</b>	<b>2.921</b>	<b>6.128.268</b>	<b>0</b>	<b>6.131.189</b>

**Changes in share capital in the latest 5 years, in DKK thousand**

	2017	2016	2015	2014	2013
Balance at 1 January.....	15.026	15.026	15.026	15.026	15.026
Balance at 31 December.....	15.026	15.026	15.026	15.026	15.026

The share capital is issued in 15.026.146 shares each DKK 1.

NOTES

	2017 USD '000	2016 USD '000	Note
<b>Fee to statutory auditors</b>			<b>1</b>
Total fee:			
Ernst & Young.....	21	16	
	21	16	
Specification of audit fee:			
Statutory audit.....	21	16	
	21	16	
<b>Other financial income</b>			<b>2</b>
Other interest income.....	26	270	
	26	270	
<b>Other financial expenses</b>			<b>3</b>
Interest, group enterprises.....	37.826	46.810	
Other interest expenses.....	27	2	
	37.853	46.812	
<b>PROPOSED DISTRIBUTION OF PROFIT</b>			<b>4</b>
Proposed dividend for the year.....	0	150.815	
Retained profit.....	407.402	259.323	
	407.402	410.138	
<b>Fixed asset investments</b>			<b>5</b>
		Investments in group enterprises	
Cost at 1 January 2017.....		6.324.604	
Cost at 31 December 2017.....		6.324.604	
Carrying amount at 31 December 2017.....		6.324.604	

NOTES

Note

**Impairment test**

Management has performed a review of impairment indicators and has - as applicable for investments, where impairment indicators are present - prepared an impairment test and thereby calculated the recoverable amount of the Company's investment in group enterprises at 31 December 2017.

The impairment method used is based on Danaher's standard internal valuation methodology. This method is based on the financial reporting as of 31 December 2017, and representative EBITDA multiplied by an assessed multiplier based on a peer-group analysis, adjusted for control premiums if applicable and non-operating assets/liabilities. The impairment test did not result in need for impairment.

**Investments in group enterprises**

Name, country of domicile, equity and profit/loss disclosures for the subsidiaries are based on financial statements for 2016 and 2017 for the respective subsidiaries. Where the financial statements are not available the internal financial reporting is used. Reference is made to addendum to note 5 on page 20-24.

**Long-term liabilities**

	1/1 2017 total liabilities	31/12 2017 total liabilities	Repayment next year	Debt outstanding after 5 years
Payables to group enterprises..	603.809	196.359	0	196.359
	<b>603.809</b>	<b>196.359</b>	<b>0</b>	<b>196.359</b>

6

## NOTES

Note

### Contingencies etc.

7

#### Joint taxation

The company is jointly taxed with Danaher Tax Administration ApS, which is the management company (Administrationselskab) for the Danish joint taxation. The company is jointly and severally unlimited liable with the other jointly taxed companies for payment of corporation tax for the income year 2013 and later, and for withholding tax on interest, royalties and dividends, which are payable on 1 July 2012 or later.

At 31 December 2017, the jointly taxed companies' net liability to SKAT is disclosed in the annual report for Danaher Tax Administration ApS, registration number - 28 31 68 87. Any subsequent assessments of the taxable income subject to joint taxation or withholding taxes on dividends, interest and royalties may entail that the Company's liability will increase.

#### Other contingencies

The company has no other contingent assets or liabilities.

#### Contingent assets

The Company has an unrecognised tax asset of USD 474 thousand (2016: USD 465 thousand), at a tax rate of 22% (2016: 22%).

The Company's deferred tax asset has not been recognised in the balance sheet due to uncertainties as to the future utilisation of the tax losses carry forward.

## Related parties

8

### Related parties having performed transactions with the company

The company's related parties comprise the significant shareholders of the Company and their subsidiaries, Board of Executives and executive and their close relatives. Related parties include also companies in which the above mentioned group of persons has material interests.

### Transactions with related parties

The related parties transactions for 2017 are shown below. All amounts in USD thousand

Transactions	Other group enterprises	Subsidiary	Parent	Total
Administration cost	21			21
Interest expense			37.826	37.826
Dividend received		445.277		445.277
Dividend paid			150.815	150.815
Repayment of loans payable			406.366	406.366
Repayment of loans receivables			150.815	150.815
<b>Balances per 31.12.17</b>				
IC loan, payable			196.359	196.359

Remuneration to the Company's Board of Executives is paid by another group enterprise.

## NOTES

	Note
<b>Significant events after the end of the financial year</b>	<b>9</b>
No events of material importance for the company's financial position have occurred after the end of the financial year.	

<b>Consolidated financial statements</b>	<b>10</b>
The ultimate parent of the group is:	

Danaher Corporation  
2200 Pennsylvania Avenue, NW  
Suite 800W  
Washington, DC 20037  
USA

The consolidated financial statement for the Danaher group can be acquired at the following link:

<https://www.sec.gov/Archives/edgar/data/313616/000031361618000038/dhr-20171231x10xk.htm>



## ACCOUNTING POLICIES

The annual report of Angel Acquisition ApS for 2017 has been presented in accordance with the provisions of the Danish Financial Statements Act for enterprises in reporting class C, large enterprise.

The accounting policies are consistent with those of last year.

### Consolidated financial statements

Referring to section 112(1) of the Danish Financial Statements Act, no consolidated financial statements are prepared. The financial statements for Angel Acquisition ApS and its group entities are part of consolidated financial statements for Danaher Corporation, USA.

## INCOME STATEMENT

### Other external expenses

Other external expenses include expenses related to administration etc.

### Investments in subsidiaries

Dividend from investments in subsidiaries is recognised in the income statement in the year of declaration.

### Financial income and expenses in general

Financial income and expenses include interest income and expenses, realised and unrealised gains and losses arising from investments in financial assets, exchange rate adjustments from debt and transactions in foreign currencies, amortisation of financial assets and liabilities as well as charges and allowances under the tax-on-account scheme etc. Financial income and expenses are recognised in the income statement by the amounts that relate to the financial year.

### Tax on profit for the year

The tax for the year, which consists of the current tax for the year and changes in deferred tax, is recognised in the income statement by the portion that may be attributed to the profit for the year, and is recognised directly in the equity by the portion that may be attributed to entries directly to the equity.

The company is jointly taxed with affiliated Danish enterprises. The current Danish corporation tax is distributed between the jointly taxed Danish enterprises in proportion to their taxable income, and with full distribution with refund regarding taxable losses. The jointly taxed companies are included in the tax-on-account scheme.

## BALANCE SHEET

### Fixed asset investments

Equity investments in subsidiaries are measured at cost. In case of indication of impairment, an impairment test must be conducted. Investments are written down to the lower of the carrying amount and the recoverable amount.

## ACCOUNTING POLICIES

### Impairment of fixed assets

The carrying amount of investments in group enterprises, which are not measured at fair value, are valued on an annual basis for indications of impairment other than reflected by amortisation and depreciation.

In the event of impairment indications, an impairment test is made for each asset or group of assets, respectively. If the net realisable value is lower than the carrying amount, write-down is provided to the lower value.

The recoverable amount is calculated at the higher of net selling price and capital value. The capital value is determined as the fair value of the expected net cash flows from the use of the asset or group of assets and the expected net cash flows from sale of the asset or group of assets after the end of its useful life.

### Receivables

Receivables are measured at amortised cost which usually corresponds to nominal value. The value is reduced by write-down to meet expected losses.

### Cash and cash equivalents

Cash and cash equivalents comprises cash balances and bank balances.

### Tax payable and deferred tax

Current tax liabilities and receivable current tax are recognised in the balance sheet as the calculated tax on the taxable income for the year, adjusted for tax on the taxable income for previous years and taxes paid on account.

Deferred tax is measured on the temporary differences between the carrying amount and the tax value of assets and liabilities.

Deferred tax assets, including the tax value of tax loss carry-forwards, are measured at the expected realisable value of the asset, either by set-off against tax on future earnings or by set-off against deferred tax liabilities within the same legal tax entity.

Deferred tax is measured on the basis of the tax rules and tax rates that under the legislation in force on the balance sheet date would be applicable when the deferred tax is expected to crystallise as current tax.

### Liabilities

Liabilities are measured at amortised cost, which usually corresponds to nominal value.

### Foreign currency translation

The financial statements are presented in USD, based on bookkeeping records expressed in USD. The foreign exchange rate in relation to DKK versus USD on the balance day is 620,07.

Transactions in foreign currencies are translated at the rate of exchange on the transaction date. Exchange differences arising between the rate on the transaction date and the rate on the payment date are recognised in the income statement as a financial income or expense.

Receivables, payables and other monetary items in foreign currencies that are not settled on the balance sheet date are translated at the exchange rate on the balance sheet date. The difference between the exchange rate on the balance sheet date and the exchange rate at the time of occurrence of the receivables or payables is recognised in the income statement as financial income or expenses.

## ACCOUNTING POLICIES

### CASH FLOW STATEMENT

With reference to section 86(4) of the Danish Financial Statements Act., no cash flow statement is prepared for the company, as its cash flows are reflected in the consolidated cash flow statement of the ultimate parent.

## Addendum to note 5 - Fixed asset investments

Entity name	Equity Currency thousand	Profit/(loss) Currency thousand	Owner- ship	Country of domicile	Currency	Source of financial information
BCK Holdings S.à.r.l.	2.015.842	-18.291	100% Luxembourg	Luxembourg	EUR	Financial statements 2016
DH Luxembourg SARL	-71	-14	100% Luxembourg	Luxembourg	EUR	Financial statements 2016
Beckman Coulter, Inc.	13.652.677	1.449.184	78% US	US	USD	Internal financial reporting
AB ScieX LLC	994.446	109.692	100% US	US	USD	Internal financial reporting
Orange Holding Corp	0	0	100% US	US	USD	No group financial reporting are available
Phenomenex Inc	797.446	11.310	100% US	US	USD	Internal financial reporting
inventx	-427	-243	100% US	US	USD	Internal financial reporting
Phenova	176	490	100% US	US	USD	Internal financial reporting
Phenomenex India Holdings LLC	3.171	0	100% India	India	USD	Internal financial reporting
BCK Luxembourg S.à.r.l.	24.556	-16	100% Luxembourg	Luxembourg	EUR	Financial statements 2016
Beckman Australia ApS	199.199	-5.874	100% Denmark	Denmark	DKK	Financial statements 2017
Beckman Coulter (Israel) Ltd.	1.709	311	100% Israel	Israel	ILS	Internal financial reporting
Beckman Coulter (U.K.) Pension Trustees Limited	0	0	100% UK	UK	GBP	No group financial reporting are available
Beckman Coulter AB	44.658	4.852	100% Sweden	Sweden	SEK	Financial statements 2016
Beckman Coulter Argentina S.A.	59.036	-2.152	86% Argentina	Argentina	USD	Financial statements 2016
Beckman Coulter Biomedical, LLC	0	0	100% US	US	USD	No group financial reporting are available
Beckman Coulter Chile Limitada	878.513	73.497	100% Chile	Chile	CLP	Internal financial reporting
Beckman Coulter Danmark ApS	5.539	1.295	100% Denmark	Denmark	DKK	Financial statements 2017
Beckman Coulter de Mexico, S.A. de C.V.	816.413	189.531	100% Mexico	Mexico	USD	Financial statements 2016
Beckman Coulter de Venezuela, S.A.	-260	53	100% Venezuela	Venezuela	USD	Internal financial reporting
Beckman Coulter do Brasil Comércio e Importação...	228.818	-37.087	100% Brazil	Brazil	BRL	Internal financial reporting
Leica do Brasil Importação e Comercio Ltda	8.722	-16.850	35% Brazil	Brazil	BRL	Internal financial reporting
Beckman Coulter Genomics Inc.	4.222.082	93.041	100% US	US	USD	Internal financial reporting
Beckman Coulter Holding S.à.r.l.	68.459	-412	100% Luxembourg	Luxembourg	USD	Financial statements 2016
Beckman Coulter Ireland Inc.	93.506	3.427	77% Panama	Panama	EUR	Internal financial reporting
Beckman Coulter España, S.A.U.	29.210	-171	100% Spain	Spain	EUR	Internal financial reporting
Beckman Coulter Korea Ltd.	25.200.610	4.676.085	100% Korea	Korea	KRW	Financial statements 2016
Beckman Coulter Nederland B.V.	84.660	29.224	100% Netherland	Netherland	EUR	Financial statements 2016
BCN Holdco Limited	23.143	-5	100% UK	UK	GBP	Financial statements 2016
Beckman Coulter d.o.o.	72.807	1.114	100% Croatia	Croatia	HRK	Financial statements 2016
Beckman Coulter Finland Oy	659	138	100% Finland	Finland	EUR	Financial statements 2017
Beckman Coulter Hong Kong Limited	2.623.658	8.696	44% Hong Kong	Hong Kong	USD	Financial statements 2016
BCHK UK Limited	9.006	-323	100% UK	UK	USD	Financial statements 2016
GL UK Holdings Limited	119.324	382	23% UK	UK	GBP	Financial statements 2016
DH Cambridge Holdings Limited	224.414	-252	100% UK	UK	GBP	Financial statements 2016
Moonsilk Holdings Limited	137.000	0	100% UK	UK	GBP	Financial statements 2016
GNZ Holdings limited	99.554	13.815	100% UK	UK	GBP	Financial statements 2016
Beckman Coulter (Dalian) Software Co.	119.202	77.279	100% China	China	CNY	Financial statements 2016
Beckman Coulter Biotechnology (Suz)	103.953	77.427	100% China	China	CNY	Financial statements 2016
Beckman Coulter Commercial Enterprise (China) C...	473.859	197.095	100% China	China	CNY	Financial statements 2016

Entity name	Equity Currency thousand	Profit/(loss) Currency thousand	Owner- ship	Country of domicile	Currency	Source of financial information
Beckman Coulter International Trading (Shanghai)...	77.381	59.791	100% China	China	CNY	Financial statements 2016
Beckman Coulter Laboratory Systems (Suzhou) Co.,...	806.092	234.435	100% China	China	CNY	Financial statements 2016
Tianjin Bonna-Agela Technologies Co., Ltd.	4.310	-7.070	100% China	China	CNY	Financial statements 2016
Bonna-Agela Technologies Inc.	318	131	100% US	US	USD	Internal financial reporting
Bonna-Agela India Pvt. Ltd.	16	-49	68% India	India	INR	Internal financial reporting
Chengdu Najie Technologies Co., Ltd.	-482	-826	100% China	China	CNY	Financial statements 2016
DH Alpha Limited	386.426	120.900	100% UK	UK	GBP	Financial statements 2016
DH Omega Ltd.	1.643.242	59.573	100% UK	UK	GBP	Financial statements 2016
KUK Holdings Limited	132.046	1.994	100% UK	UK	GBP	Financial statements 2016
Molecular Devices (UK) Limited	8.562	1.581	85% UK	UK	GBP	Financial statements 2016
Beckman Coulter India Private Limited	4.158.151	229.478	100% India	India	INR	Internal financial reporting
Beckman Coulter Magyarország Kft	1.176.591	45.606	100% Hungary	Hungary	HUF	Financial statements 2016
Beckman Coulter Malaysia Sdn Bhd	12.874	649	100% Malaysia	Malaysia	MYR	Financial statements 2016
Beckman Coulter Polska sp. z o.o.	7.199	1.417	100% Poland	Poland	PLN	Financial statements 2016
Beckman Coulter South Africa (Proprietary) Limited	253.001	29.716	100% South Africa	South Africa	ZAR	Financial statements 2016
Ormc south Africa Proprietary Limited	14.704	-2.149	100% South Africa	South Africa	ZAR	Financial statements 2016
Beckman Coulter Portugal Unipessoal Lda.	2.048	379	100% Portugal	Portugal	EUR	financial statement 2016
Beckman Coulter Puerto Rico Inc.	24.534	-2.201	100% US	US	USD	Internal financial reporting
Beckman Coulter Servicios, S. de R.L. de C.V.	7.597	4.924	100% Mexico	Mexico	MXN	Financial statements 2016
AB ScieX SA de CV	27.709	2.177	100% Mexico	Mexico	MXN	Internal financial reporting
Beckman Coulter Singapore Pte. Ltd.	17.745	30	100% Singapore	Singapore	SGD	Financial statements 2016
Beckman Coulter Taiwan Inc.	1.027.289	10.397	100% Taiwan	Taiwan	TWD	Financial statements 2016
Beckman Holdings Limited	90.792	40.440	39% UK	UK	GBP	Financial statements 2016
Beckman Coulter Biyomedikal Ürünler Sanayi ve T...	173.559	7.183	76% Turkey	Turkey	TRY	Financial statements 2016
DX Laboratuvar cozumleri A.S	-476	-580	100% Turkey	Turkey	TRY	Internal financial reporting
Cepheid	3.334.248	-124.071	100% US	US	USD	Internal financial reporting
Cepheid AB	83.379	14.327	100% Sweden	Sweden	SEK	Financial statements 2016
Cepheid benelux BVBA	29	17	100% Belgium	Belgium	EUR	Financial statements 2016
Cepheid Brasil Exportacao e Comercio de Produtos de Diagn...	3.278	862	100% Brazil	Brazil	BRL	financial statement 2016
Cepheid Canadian Corporation	0	0	100% US	US	USD	No group financial reporting are available
Cepheid Europe SAS	5.643	713	100% France	France	EUR	Financial statements 2016
Cepheid HBDC SAS	3.274	765	100% US	US	EUR	Financial statements 2016
Cepheid GK	3.114.595	-173.294	100% Japan	Japan	JPY	Internal financial reporting
Cepheid GmbH	5.677	-171	54% Germany	Germany	EUR	Financial statements 2016
Cepheid HBDC	0	0	100% US	US	USD	Internal financial reporting
Cepheid Holdings Pty Limited	21.660	406	100% Australia	Australia	AUD	Internal financial reporting
Cepheid India Private Limited	183.973	136.149	100% India	India	INR	Internal financial reporting
Cepheid Lodi, LLC	0	0	100% US	US	USD	Internal financial reporting

Entity name	Equity Currency thousand	Profit/(loss) Currency thousand	Owner- ship	Country of domicile	Currency	Source of financial information
Cepheid Limited	6.649	619	100%	Hong Kong	USD	Internal financial reporting
Cepheid (Shanghai) Commerce and trade	1.864	-75	100%	Shanghai	CNY	Internal financial reporting
Cepheid (Shanghai) Diagnostics Co. Ltd	-2.871	-1.882	100%	Shanghai	CNY	Internal financial reporting
Cepheid Proprietary Limited	43.472	12.999	100%	South Africa	ZAR	Financial statements 2016
Cepheid S.r.l.	1.239	11	100%	Italy	EUR	Financial statements 2016
Cepheid Singapore Pte. Ltd.	9	-49	100%	Singapore	USD	Financial statements 2016
Cepheid UK Limited	1.309	-354	100%	UK	GBP	Financial statements 2016
DH Life Sciences LLC	-105	-105	100%	US	USD	Internal financial reporting
DH Technologies Development Pte Ltd.	-103.291	-1.584	77%	Singapore	USD	Financial statements 2016
DH Singapore Holdings Pte. Ltd.	287.424	89	100%	Singapore	SGD	Internal financial reporting
DH ScieX Singapore Pte. Ltd.	18.087	-874	100%	Singapore	USD	Financial statements 2016
Videojet Technologies (S) PTE. LTD.	-2.275	1.356	100%	Singapore	SGD	Financial statements 2016
Advanced vision Technology (A.V.T.) Ltd.	0	0	100%	Israel	ILS	No group financial reporting are available
Advanced Vision Technology A.V.T. (Germany)	0	0	100%	Germany	EUR	No group financial reporting are available
AVT EMEA CVBA	0	0	100%	Belgium	EUR	No group financial reporting are available
AVT, Advanced Vision Technology, Inc.	0	0	100%	US	USD	No group financial reporting are available
Graphics Microsystems, Inc.	0	0	100%	US	USD	No group financial reporting are available
DHR MENA FZ-LLC	8.520	741	100%	Saudi Arabia	AED	Internal financial reporting
Diagnostic Systems Laboratories (India) Private Limited	1.923	0	100%	India	INR	Internal financial reporting
Hybritech Incorporated	234.069	12.344	100%	US	USD	Internal financial reporting
Hybritech Cancer Research Incorporated	1.017	17	100%	US	USD	Internal financial reporting
Hybritech International Incorporated	-19.605	0	100%	US	USD	Internal financial reporting
IAF Corporation Pty Ltd	0	0	100%	Australia	AUD	Internal financial reporting
Diagnostic Systems Laboratories Australia Pte	4.279	1.075	100%	Australia	AUD	Internal financial reporting
Inhybin Pty Limited	0	0	100%	Australia	AUD	Internal financial reporting
Iris International Europe GmbH	167.116	-43	100%	Switzerland	CHF	Internal financial reporting
Beckman Coulter Eurocenter SA	62.032	2.930	100%	Switzerland	CHF	Financial statements 2016
BECKMAN COULTER INTERNATIONAL SA	93.295	11.692	100%	Switzerland	CHF	Financial statements 2016
BECKMAN SAUDI ARABIA CO LTD (50%)	30.838	1.309	75%	Saudi Arabia	SAR	Financial statements 2016
Orbisphère Management Holding Sarl	90.596	5.782	68%	Switzerland	CHF	Financial statements 2016
Hach Lange Sarl (Switzerland)	39.155	7.863	100%	Switzerland	CHF	Financial statements 2016
Andia S.A.S.	1.080	-470	100%	Colombia	COP	Financial statement 2016
Hach South Africa Pty. Ltd.	27.251	10.824	100%	South Africa	ZAR	financial statement 2016
AB ScieX South Africa (Proprietary) Limited	-5.927	404	100%	South Africa	ZAR	Internal financial reporting
Lipesa Colombia S.A.S.	65.322	5.763	98%	Colombia	COP	Financial statements 2016
Lipeq S.A.	2.719	539	98%	Ecuador	USD	Financial statements 2016
Lipesa do Brasil Especialidades Químicas Ltda	-10.329	-8.448	100%	Brazil	BRL	Internal financial reporting
NBH Switzerland Holding Sarl	142.298	-27	54%	Luxembourg	USD	Financial statements 2016
Iris International Inc.	302.356	-8.541	100%	US	USD	Internal financial reporting
Arista Molecular, Inc	-3.753	0	100%	US	USD	Internal financial reporting

Entity name	Equity Currency thousand	Profit/(loss) Currency thousand	Owner- ship	Country of domicile	Currency	Source of financial information
KMB S.a.r.l.	277.183	-442	92%	Luxembourg	EUR	Financial statements 2016
X-Rite Holdings SARL	454.552	-24.152	73%	Luxembourg	USD	Financial statements 2016
Beckman Luxembourg SARL	320.409	-149	100%	Luxembourg	EUR	Financial statements 2016
Beckman Finance Sarl	347.515	-14	100%	Luxembourg	EUR	Financial statements 2016
WA3 SARL	347.546	-16	100%	France	EUR	Financial statements 2016
Beckman Coulter Holding ApS	350.132	-563	100%	Denmark	EUR	Financial statements 2017
X-RITE EUROPE GMBH (FKA XEG 1234 GMBH)	21.340	3.547	82%	Switzerland	CHF	Financial statements 2016
VIDEOJET TECHNOLOGIES SUISSE GMBH (FKA WILE)	5.151	175	100%	Switzerland	CHF	Financial statements 2016
X-Rite Asia Pacific Limited	15.418	792	100%	Hong Kong	USD	Financial statements 2016
X-Rite India Private limited	11.277	1.061	100%	India	INR	Financial statements 2016
X-Rite Switzerland GMBH	13.466	808	100%	Switzerland	CHF	Financial statements 2016
Leica Microsystems Inc.	99.653	24.346	100%	US	USD	Financial statements 2016
Bloptigen, Inc.	9.443	-690	100%	US	USD	Internal financial reporting
Devicor Medical Products Holdings, Inc.	0	0	100%	US	USD	Internal financial reporting
Devicor Medical Products, Inc.	402.965	13.558	100%	US	USD	No group financial reporting are available
Artemis Medical, Inc.	0	0	100%	US	USD	Internal financial reporting
Devicor Medical Canada, Inc.	1.113	260	100%	Canada	USD	Internal financial reporting
Devicor Medical Cayman Limited	0	0	100%	Cayman	CAD	Internal financial reporting
Devicor Medical H.K. Limited	-1.524	-361	100%	Hong Kong	USD	Internal financial reporting
Devicor Medical Device (Shanghai)	-1.662	-4.179	100%	Shanghai	USD	Internal financial reporting
Devicor Medical Europe Gmbh	1.140	547	100%	Germany	CNY	Financial statements 2016
Devicor Medical France SAS	2.015	-25	100%	France	EUR	Financial statements 2016
Devicor Medical Germany Gmbh	-3.833	864	100%	Germany	EUR	Financial statements 2016
Devicor Medical Holdings LLC	0	0	100%	US	EUR	Financial statements 2016
Devicor Medical Italy S.r.l.	5.984	227	44%	Italy	USD	No group financial reporting are available
Devicor Medical Japan K.K.	0	0	100%	Japan	MXN	Financial statements 2016
Devicor Medical Poland sp. z o.o.	5.582	77	100%	Poland	YEN	No group financial reporting are available
Devicor Medical Products de Mexico, S. de R.	5.287	765	99%	Mexico	PLN	Financial statements 2016
Devicor Medical Products Servicios, S. de R.L.	-4.606	-255	99%	Mexico	EUR	Financial statements 2016
Devicor Medical Puerto Rico LLC	0	0	100%	Puerto Rico	JPY	Financial statements 2016
Devicor Medical UK Limited	78	-23	100%	UK	USD	No group financial reporting are available
Devicor Medical Korea Limited	68.087	-201.180	100%	Korea	GBP	Financial statements 2016
Leica biosystems Imaging, Inc.	345.168	-5.921	100%	US	KRW	Financial statements 2016
Leica biosystems Richmond Inc	0	0	100%	US	USD	Internal financial reporting
						No group financial reporting are available

## Addendum to note 5 - Fixed asset investments

Entity name	Equity Currency thousand	Profit/(loss) Currency thousand	Owner- ship	Country of domicile	Currency	Source of financial information
Lumigen, Inc	321.595	28.580	100% US	100% US	USD	Internal financial reporting
Molecular Devices, LLC	-59.318	22.938	100% US	100% US	USD	Internal financial reporting
Blueshift Biotechnologies, LLC	0	0	100% US	100% US	USD	No group financial reporting are available
Molecular Devices (Germany) GmbH	3.346	335	59% Germany	Germany	EUR	Financial statements 2016
Molecular Devices (Hong Kong) Limited	8.200	289	100% Hong Kong	Hong Kong	USD	Financial statements 2016
Molecular Devices (Shanghai) Limited	57.339	50.140	100% Shanghai	Shanghai	CNY	Financial statements 2016
Radfometer HK Limited	196.543	-36.040	21% Hong Kong	Hong Kong	HKD	Financial statements 2016
DH NZ Holdings	0	-5	100% New Zealand	New Zealand	NZD	Internal financial reporting
Molecular Devices Instrumentação do Brasil Ltda.	-203	226	99% Brazil	Brazil	BRL	Internal financial reporting
Molecular Devices Korea, LLC	2.077.317	-398.789	100% Korea	Korea	KRW	Internal financial reporting
Leica Microsystems SAS	4.720	646	100% France	France	EUR	Financial statements 2016
Beckman Coulter France ApS	54.112	52.627	100% Denmark	Denmark	EUR	Financial statements 2017
Beckman Coulter France S.A.S.	151.198	8.446	100% France	France	EUR	Financial statements 2016
Immunotech SAS	44.675	11.961	100% France	France	EUR	Financial statements 2016
Immunotech Sro	1.403.780	296.265	100% Czech Republic	Czech Republic	CZK	Financial statements 2016
Beckman Coulter Ceska republika s.r.o.	702.984	827.320	100% Czech Republic	Czech Republic	CZK	Financial statements 2016
Beckman Coulter Limited Liability Company	1.281	214	99% Russia	Russia	RUB	Financial statements 2016
Beckman Coulter Slovenska republika s.r.o.	3.148	285	100% Slovakia	Slovakia	EUR	Financial statements 2016